argenx is a biotechnology company that develops antibody-based therapies for severe autoimmune diseases, including its FcRn-blocker Vyvgart.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 55 | New buy | 1,214 | $886,524 | 0.0% |
| Ancora | 42 | Holds (flat) | 8 | $5,842 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-03-30 | Alan Armstrong senate | BUY | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-20.